HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Subscribe To Our Newsletter & Stay Updated